Alpha Tau Medical Ltd. (DRTS) NASDAQ
10.04
-0.92(-8.39%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
10.04
-0.92(-8.39%)
Currency In USD
| Previous Close | 10.96 |
| Open | 10.74 |
| Day High | 10.74 |
| Day Low | 9.76 |
| 52-Week High | 11.62 |
| 52-Week Low | 2.81 |
| Volume | 857,991 |
| Average Volume | 500,543 |
| Market Cap | 883.62M |
| PE | -14.99 |
| EPS | -0.67 |
| Moving Average 50 Days | 8.07 |
| Moving Average 200 Days | 5.75 |
| Change | -0.92 |
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
GlobeNewswire Inc.
Feb 24, 2026 2:00 PM GMT
- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong coll
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
GlobeNewswire Inc.
Jan 29, 2026 2:00 PM GMT
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treat